ArticleContemporary clinical trials2025

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial.

Mark J Giganti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.